BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21748770)

  • 1. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
    Torres DM; Jones FJ; Shaw JC; Williams CD; Ward JA; Harrison SA
    Hepatology; 2011 Nov; 54(5):1631-9. PubMed ID: 21748770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
    Ratziu V; Giral P; Jacqueminet S; Charlotte F; Hartemann-Heurtier A; Serfaty L; Podevin P; Lacorte JM; Bernhardt C; Bruckert E; Grimaldi A; Poynard T;
    Gastroenterology; 2008 Jul; 135(1):100-10. PubMed ID: 18503774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.
    Ratziu V; Charlotte F; Bernhardt C; Giral P; Halbron M; Lenaour G; Hartmann-Heurtier A; Bruckert E; Poynard T;
    Hepatology; 2010 Feb; 51(2):445-53. PubMed ID: 19877169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
    Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Oliver D; Bacon BR
    Hepatology; 2003 Oct; 38(4):1008-17. PubMed ID: 14512888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.
    Aithal GP; Thomas JA; Kaye PV; Lawson A; Ryder SD; Spendlove I; Austin AS; Freeman JG; Morgan L; Webber J
    Gastroenterology; 2008 Oct; 135(4):1176-84. PubMed ID: 18718471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.
    Schwimmer JB; Middleton MS; Deutsch R; Lavine JE
    Aliment Pharmacol Ther; 2005 Apr; 21(7):871-9. PubMed ID: 15801922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
    Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
    Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
    Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA
    Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
    Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
    Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE
    Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
    Promrat K; Lutchman G; Uwaifo GI; Freedman RJ; Soza A; Heller T; Doo E; Ghany M; Premkumar A; Park Y; Liang TJ; Yanovski JA; Kleiner DE; Hoofnagle JH
    Hepatology; 2004 Jan; 39(1):188-96. PubMed ID: 14752837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
    Kilicdag EB; Bagis T; Zeyneloglu HB; Tarim E; Aslan E; Haydardedeoglu B; Erkanli S
    Hum Reprod; 2005 Apr; 20(4):894-9. PubMed ID: 15618250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
    Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
    Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
    Mulligan K; Yang Y; Wininger DA; Koletar SL; Parker RA; Alston-Smith BL; Schouten JT; Fielding RA; Basar MT; Grinspoon S
    AIDS; 2007 Jan; 21(1):47-57. PubMed ID: 17148967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
    Corey KE; Chalasani N
    Hepatology; 2011 Nov; 54(5):1503-5. PubMed ID: 21953015
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
    Perez A; Zhao Z; Jacks R; Spanheimer R
    Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.
    Harrison SA; Torgerson S; Hayashi P; Ward J; Schenker S
    Am J Gastroenterol; 2003 Nov; 98(11):2485-90. PubMed ID: 14638353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
    Omer Z; Cetinkalp S; Akyildiz M; Yilmaz F; Batur Y; Yilmaz C; Akarca U
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):18-23. PubMed ID: 19667999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.